Secukinumab
Indication
Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (NICE TA407)
NICE TA407 - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Red
Brand:
Cosentyx ®
Nice TA:
407
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
Secukinumab is recommended, within its marketing authorisation, as an option for treating active ankylosing spondylitis in adults whose disease has responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors). The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.
Assess the response to secukinumab after 16 weeks of treatment and only continue if there is clear evidence of response, defined as:
a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the more units and
a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.
When using BASDAI and spinal pain VAS scores, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the responses to the questionnaires, and make any adjustments they consider appropriate.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: